Follow The Filings

REGN Regeneron

Health Care, filed as REGENERON PHARMACEUTICALS (COM), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

Bought by 3 managers in 2026 Q2, sold by 1

  • 1 Owner
  • #230
  • Max 0.9%
  • Master 0.19%
  • $2.6M
  • 1 reduce

In 2026 Q3 Murphy Pohlad trimmed Regeneron.

Who owns this now

Largest portfolio weights among holders, up to 0.9% (Murphy Pohlad, Murphy Pohlad Asset Management). Not free-float ownership.

  1. Murphy Pohlad Reduce 0.92%

Who owns REGN

Sorted by value, long equity only, as of 2026 Q3.

History
Murphy Pohlad, Murphy Pohlad Asset Management 0.92% Reduce −0.6% 3,488 $2.6M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by REGN's executives, directors and 10% owners in the last 12 months, from their Form 4s

All REGN insider trades
  • None no insider bought on the open market
  • $281K sold by 1 insider outside a trading plan
  • $11.6M sold by 7 insiders under 10b5-1 plans
  1. Andrew J Murphy Co-Chief Scientific Officer
    Planned sale
    $3.2M 4,147 shares at $772.70 8% of stake
    Traded Oct 14 Filed Oct 15
    ↗
  2. Kathryn Guarini Director
    Planned sale
    $340K 400 shares at $850.00 40% of stake
    Traded Sep 2 Filed Sep 3
    ↗
  3. Marion McCourt EVP Commercial
    Planned sale
    $2M 2,346 shares at $853.56 16% of stake
    Traded Sep 2–3 Filed Sep 3
    ↗
  4. Kathryn Guarini Director
    Planned sale
    $320K 400 shares at $800.00 40% of stake
    Traded Aug 10 Filed Aug 12
    ↗
  5. Huda Y Zoghbi Director
    Planned sale
    $640K 800 shares at $800.00 32% of stake
    Traded Aug 10 Filed Aug 12
    ↗
  6. Arthur F Ryan Director
    Planned sale
    $130K 200 shares at $650.15 1.1% of stake
    Traded Jul 2 Filed Jul 7
    ↗
  7. Arthur F Ryan Director
    Planned sale
    $71K 100 shares at $705.24 0.6% of stake
    Traded May 1 Filed May 4
    ↗
  8. Arthur F Ryan Director
    Planned sale
    $78K 100 shares at $777.27 0.6% of stake
    Traded Apr 1 Filed Apr 3
    ↗
  9. Arthur F Ryan Director
    Planned sale
    $79K 100 shares at $785.50 0.6% of stake
    Traded Mar 2 Filed Mar 3
    ↗
  10. Huda Y Zoghbi Director
    Planned sale
    $1.3M 1,638 shares at $781.33 49% of stake
    Traded Feb 19 Filed Feb 23
    ↗
  11. Jason Pitofsky SVP Controller
    Planned sale
    $1.6M 2,036 shares at $778.52 32% of stake
    Traded Feb 9 Filed Feb 11
    ↗
  12. Arthur F Ryan Director
    Planned sale
    $78K 100 shares at $778.53 0.6% of stake
    Traded Feb 9 Filed Feb 11
    ↗
  13. Bonnie L Bassler Director
    Planned sale
    $1.2M 1,500 shares at $800.00 47% of stake
    Traded Jan 7 Filed Jan 8
    ↗
  14. Bonnie L Bassler Director
    Planned sale
    $570K 760 shares at $750.00 33% of stake
    Traded Nov 20, 2025 Filed Nov 24, 2025
    ↗
  15. Jason Pitofsky VP Controller
    Sale
    $281K 431 shares at $651.43 9.2% of stake
    Traded Nov 7, 2025 Filed Nov 10, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 18 share withholdings for taxes, 17 stock grants, 17 option exercises, and 1 gift.

Congress

11 members of Congress traded REGN in the last three years: 6 buys and 19 sales. 5 members listed it in 2025 annual reports.

All Congress trades
  1. Alan Armstrong R-OK Buy $1K–$15K Mar 27 filed Jul 21
  2. Gilbert Ray Cisneros, Jr. D-CA-31 Sell $1K–$15K May 15 filed Jun 8
  3. Julia Letlow R-LA-5 Buy $1K–$15K Feb 12 filed Mar 12
  4. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Nov 18, 2025 filed Dec 15, 2025
  5. Robert P. Bresnahan, Jr. R-PA-8 Buy $1K–$15K May 15, 2025 filed Jun 9, 2025
  6. Byron Donalds R-FL-19Spouse Sell $1K–$15K Apr 10, 2025 filed May 24, 2025

SEC filings

Recent issuer filings from EDGAR, 18 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 1.01,2.02,8.01 Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A DEFINITIVE PROXY STATEMENT Filing Doc
DEFA14A DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS Filing Doc
8-K 2.02 Filing Doc
SCHEDULE 13G/A — Filing Doc
10-K Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated about 4 hours ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $13.12B $14.2B $14.34B
Net income $3.95B $4.41B $4.5B
Net margin * 30.1% 31.1% 31.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $19.48B $18.66B $18.02B
Total non-current assets * $13.6B $19.1B $22.54B
Total assets $33.08B $37.76B $40.56B
Total current liabilities $3.42B $3.94B $4.37B
Total non-current liabilities * $3.68B $4.46B $4.93B
Total equity $25.97B $29.35B $31.26B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $4.59B $4.42B $4.98B
Cash from investing -$3.19B -$2.47B -$0.629B
Cash from financing -$1.79B -$2.2B -$3.72B
Net change in cash -$381.6M -$248.8M $634.7M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.